大连医科大学学报
大連醫科大學學報
대련의과대학학보
Journal of Dalian Medical University
2015年
5期
502-506
,共5页
王玉%邢嵘%万山荣%王阳
王玉%邢嶸%萬山榮%王暘
왕옥%형영%만산영%왕양
去势抵抗性前列腺癌%雄激素受体拮抗剂%Enzalutamide%ARN-509%ONC1-13B
去勢牴抗性前列腺癌%雄激素受體拮抗劑%Enzalutamide%ARN-509%ONC1-13B
거세저항성전렬선암%웅격소수체길항제%Enzalutamide%ARN-509%ONC1-13B
castration-resistant prostate cancer%AR antagonists%Enzalutamide%ARN-509%ONC1-13B
前列腺癌的进展与雄激素受体( androgen receptor,AR)以及AR反应通路相关,进展期前列腺癌患者需接受雄激素阻断治疗,而去势抵抗性前列腺癌( castration-resistant prostate cancer,CRPC)的临床治疗更加复杂。 Enz-alutamide,ARN-509,ONC1-13B三种新型AR拮抗剂是用于AR的靶向药物,临床研究正在进行中。 AR拮抗剂效果明显且副作用小,因此应用这一类药物治疗CRPC的方法便日益凸显其重要性。
前列腺癌的進展與雄激素受體( androgen receptor,AR)以及AR反應通路相關,進展期前列腺癌患者需接受雄激素阻斷治療,而去勢牴抗性前列腺癌( castration-resistant prostate cancer,CRPC)的臨床治療更加複雜。 Enz-alutamide,ARN-509,ONC1-13B三種新型AR拮抗劑是用于AR的靶嚮藥物,臨床研究正在進行中。 AR拮抗劑效果明顯且副作用小,因此應用這一類藥物治療CRPC的方法便日益凸顯其重要性。
전렬선암적진전여웅격소수체( androgen receptor,AR)이급AR반응통로상관,진전기전렬선암환자수접수웅격소조단치료,이거세저항성전렬선암( castration-resistant prostate cancer,CRPC)적림상치료경가복잡。 Enz-alutamide,ARN-509,ONC1-13B삼충신형AR길항제시용우AR적파향약물,림상연구정재진행중。 AR길항제효과명현차부작용소,인차응용저일류약물치료CRPC적방법편일익철현기중요성。
Prostate cancer is one of the common malignant tumors in male reproductive system.It is currently accepted that the progression of prostate cancer is related to androgen receptor ( AR) and AR reaction pathway.The clinical treat-ment becomes more complicated when it progresses to castration-resistant prostate cancer ( CRPC) .The clinical trial have shown that three novel AR antagonists, including Enzalutamide, ARN-509and ONC1-13B, are effective and have minor adverse reactions.Therefore, application of AR antagonists in the treatment of CRPC is becoming increasingly important.